[1]张晶晶,岳丽娟,王 莹,等.奥拉帕利联合奈达铂腹腔热灌注化疗治疗上皮性卵巢癌疗效观察[J].陕西医学杂志,2021,50(12):1566-1569.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.025]
　ZHANG Jingjing,YUE Lijuan,WANG Ying,et al.Efficacy of olaparib combined with nedaplatin hyperthermic intraperitoneal chemotherapy in treatment of epithelial ovarian cancer[J].,2021,50(12):1566-1569.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.025]
点击复制

奥拉帕利联合奈达铂腹腔热灌注化疗治疗上皮性卵巢癌疗效观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年12期
页码:
1566-1569
栏目:
药物与临床
出版日期:
2021-12-05

文章信息/Info

Title:
Efficacy of olaparib combined with nedaplatin hyperthermic intraperitoneal chemotherapy in treatment of epithelial ovarian cancer
作者:
张晶晶1; 岳丽娟1; 王 莹1; 朱宏财1; 胡 勇2
(1.汉中市中心医院肿瘤内科,陕西 汉中 723000; 2.汉中市中心医院放疗科,陕西 汉中 723000)
Author(s):
ZHANG Jingjing; YUE Lijuan; WANG Ying; ZHU Hongcai; HU Yong
(Department of Oncology,Hanzhong Central Hospital,Hanzhong 723000,China)
关键词:
上皮性卵巢癌;  聚腺苷二磷酸核糖聚合酶抑制剂;  腹腔热灌注化疗;  奥拉帕利;  奈达铂;  肿瘤标志物
Keywords:
Epithelial ovarian cancer;  PARP inhibitor;  HIPEC;  Olaparib;  Nedaplatin;  Tumor marker
分类号:
R 737.31
DOI:
DOI:10.3969/j.issn.1000-7377.2021.12.025
文献标志码:
A
摘要:
目的:观察聚腺苷二磷酸核糖聚合酶(PARP)抑制剂奥拉帕利联合奈达铂腹腔热灌注化疗(HIPEC)治疗上皮性卵巢癌(EOC)的疗效。方法:选取EOC患者54例作为研究对象,采用随机数字表法随机分为对照组(27例,在常规治疗基础上加用奈达铂腹腔热灌注化疗)和观察组(27例,在对照组基础上联合奥拉帕利进行治疗)。比较两组患者治疗前后血清肿瘤标志物糖类抗原125(CA125)、血清人附睾蛋白4(HE4)水平、白细胞(WBC)计数、近期治疗效果、远期生存率以及不良反应发生情况。结果:治疗前两组患者CA125、HE4水平及WBC计数比较差异无统计学意义(均P>0.05),治疗后观察组CA125、HE4水平分别低于对照组(均P<0.05)。观察组患者近期有效率高于对照组(P<0.05)。两组患者1年生存率比较差异无统计学意义(P>0.05),观察组2年和3年生存率高于对照组(均P<0.05)。两组患者肾功能不全、骨髓抑制、听力异常、腹膜炎、脱发等不良反应发生情况比较,差异无统计学意义(均P>0.05)。结论:奥拉帕利联合奈达铂腹腔热灌注化疗能提高EOC患者近期疗效及远期生存率,且不良反应发生率无明显升高。
Abstract:
Objective:To observe the efficacy of polyadenosine diphosphate ribose polymerase(PARP)inhibitor olaparil combined with nedaplatin hyperthermic intraperitoneal chemotherapy(HIPEC)in the treatment of epithelial ovarian cancer(EOC).Methods:54 EOC patients were selected and randomly divided into the control group(27 cases)and the observation group(27 cases).The control group received HIPEC with nedaplatin on the basis of conventional treatment.The observation group was treated with olaparib on the basis of the control group.The levels of carbohydrate antigen 125(CA125),serum human epididymal protein 4(HE4)and white blood cell(WBC)count before and after treatment,and short-term treatment effect,long-term survival rate and occurrence of adverse reactions were compared between the two groups of patients.Results:There was no significant difference in the levels of CA125,HE4 and WBC count between the two groups before treatment(all P>0.05).After treatment,the levels of CA125 and HE4 in the observation group were lower than those in the control group(all P<0.05).The short-term effective rate in the observation group was higher than that in the control group(P<0.05).There was no significant difference in the 1-year survival rate between the two groups(P>0.05).The 2-year and 3-year survival rates of the observation group were higher than those of the control group(all P<0.05).There was no statistically significant difference in the occurrence of adverse reactions such as renal insufficiency,bone marrow suppression,abnormal hearing,peritonitis,and alopecia between the two groups(all P>0.05).Conclusion:Olaparib combined with nedaplatin hyperthermic intraperitoneal chemotherapy can improve the short-term efficacy and long-term survival rate of EOC patients,and the incidence of adverse reactions does not increase significantly.

参考文献/References:

[1] 闫 旭,张爱臣,佟玲玲.聚腺苷二磷酸核糖聚合酶抑制剂治疗卵巢癌新进展[J].中国计划生育和妇产科,2020,12(11):13-16.
[2] 刘昀昀,林仲秋.多腺苷二磷酸核糖聚合酶抑制剂联合抗血管生成药物治疗卵巢癌的不良事件及处理[J].中国实用妇科与产科杂志,2020,36(9):900-904.
[3] Labidi-Galy SI,Rouge T,Derbel O,et al.Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers[J].Gynecologic Oncology,2019,155(2):262-269.
[4] Winter KS,Hofmann FO,Thierfelder KM,等.基于实体瘤疗效评价标准1.1版(RECIST1.1)中的体积阈值:肝转移瘤治疗效果评估[J].国际医学放射学杂志,2019,42(1):121.
[5] 陈祥艳,陈 聪,孙 云,等.益肾抗瘤方联合IL-2腹腔灌注治疗卵巢癌相关腹水的疗效观察[J].中国临床药理学与治疗学,2018,23(12):1408-1414.
[6] 李 斌,黄 蓉,李红霞,等.党黄抗癌汤配合肿瘤细胞减灭术中腹腔热灌注及化疗治疗Ⅳ期上皮性卵巢癌临床研究[J].陕西中医,2019,40(11):1562-1565.
[7] 钟 亮,刘清壮,蔡茂德.Ⅲ、Ⅳ期上皮性卵巢癌术后腹腔辅助化疗临床观察[J].陕西医学杂志,2020,49(2):193-196.
[8] 刘瑞丽,刘小红,李会荣,等.主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液效果观察[J].陕西医学杂志,2019,48(12):1630-1633.
[9] 徐 赢.持续循环与单灌单抽腹腔热灌注化疗治疗卵巢癌腹腔积液临床研究[J].中国药物与临床,2020,20(4):596-599.
[10] 宫 晗,聂 丹,黄 玥,等.聚腺苷酸二磷酸核糖聚合酶抑制剂在复发性卵巢癌维持治疗中的作用[J].中华妇幼临床医学杂志:电子版,2021,17(1):1-6.
[11] 姜松耀,赵良超,严晓伟,等.紫杉醇腹腔热灌注联合静脉化疗转化治疗晚期胃癌(附1例报告)[J].外科理论与实践,2020,25(2):66-68.
[12] 马书丽,李 静,袁 媛,等.卵巢上皮癌患者CA125和HE4水平及其临床意义分析[J].国际检验医学杂志,2019,40(14):1759-1761.
[13] 林评樱,吴 媛,李钟辉.CA125与HE4检测在卵巢癌诊断及病情监测中的应用价值[J].临床医学工程,2019,26(6):787-788.
[14] 胡天祺,杨梦琪,杨 红,等.益气养阴方对卵巢癌术后患者化疗不良反应及生存质量的影响[J].陕西中医,2021,42(4):434-437.
[15] 狄子杨,唐 强,狄茂军,等.腹腔热灌注化疗治疗晚期结直肠癌的疗效分析[J].临床外科杂志,2020,28(5):433-436.
[16] 刘 欣,张国楠.腹腔热灌注化疗治疗卵巢癌的研究进展[J].肿瘤预防与治疗,2021,34(2):160-165.
[17] 丁平安,杨沛刚,田 园,等.腹腔热灌注化疗联合全身系统化疗及阿帕替尼转化治疗对胃癌腹膜转移的疗效[J].中国肿瘤临床,2021,48(8):409-414.
[18] 彭友晋,王玲玲,李飞浪,等.大剂量紫杉醇联合顺铂腹腔灌注治疗晚期上皮性卵巢癌的临床疗效观察[J].实用医院临床杂志,2020,17(6):110-113.
[19] 葛宏升,周 军,雷 霆.中药联合常规化疗对乳腺癌术后患者免疫功能及远期转移率的影响[J].现代中西医结合杂志,2019,28(14):1544-1547.
[20] 高玉青,丁 慧,丁雪华.肿瘤细胞减灭术联合新辅助化疗治疗晚期卵巢癌的疗效分析[J].癌症进展,2019,17(15):1835-1838.

相似文献/References:

[1]孙红艳,王改华.不同手术方式治疗卵巢癌临床效果及对患者生育功能的影响[J].陕西医学杂志,2019,(2):213.
　SUN Hongyan,WANG Gaihua..Clinical effects of different surgical treatments on 125 patients with ovarian  cancer and their influence on reproductive function[J].,2019,(12):213.
[2]王 琰,王 静,张志明,等.卵巢肿瘤患者尿液中间皮素联合人附睾蛋白4检测及临床意义[J].陕西医学杂志,2019,(8):1088.
　WANG Yan,WANG Jing,ZHANG Zhiming,et al.Predictive value between MSLN and HE4 in urine levels in patients with  early stage of epithelial ovarian cancer[J].,2019,(12):1088.
[3]钟 亮,刘清壮,蔡茂德.III、IV期上皮性卵巢癌术后腹腔辅助化疗临床观察*[J].陕西医学杂志,2020,49(2):193.
　ZHONG Liang,LIU Qingzhuang,CAI Maode..Application of intraperitoneal chemotherapy in postoperative adjuvant treatment of stage Ⅲ and Ⅳ epithelial ovarian cancer[J].,2020,49(12):193.
[4]孙丹丹,张 颖,马善波,等.膜相关环指蛋白7在上皮性卵巢癌组织和细胞中的表达及作用机制研究[J].陕西医学杂志,2024,(6):842.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.026]
　SUN Dandan,ZHANG Ying,MA Shanbo,et al.Expression and mechanism of membrane-associated ring finger protein 7 in epithelial ovarian cancer tissues and cells[J].,2024,(12):842.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.026]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2017SF-074)
更新日期/Last Update: 2021-12-07